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Abstract -Amyloid (A) related pathology shows a
range of lesions which diVer both qualitatively and quanti-
tatively. Pathologists, to date, mainly focused on the assess-
ment of both of these aspects but attempts to correlate the
Wndings with clinical phenotypes are not convincing. It has
been recently proposed in the same way as  and  synuc-
lein related lesions, also A related pathology may follow a
temporal evolution, i.e. distinct phases, characterized by a
step-wise involvement of diVerent brain-regions. Twenty-
six independent observers reached an 81% absolute
agreement while assessing the phase of A, i.e. phase
1 = deposition of A exclusively in neocortex, phase
2 = additionally in allocortex, phase 3 = additionally in
diencephalon, phase 4 = additionally in brainstem, and
phase 5 = additionally in cerebellum. These high agreement
rates were reached when at least six brain regions were
evaluated. Likewise, a high agreement (93%) was reached
while assessing the absence/presence of cerebral amyloid
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angiopathy (CAA) and the type of CAA (74%) while exam-
ining the six brain regions. Of note, most of observers
failed to detect capillary CAA when it was only mild and
focal and thus instead of type 1, type 2 CAA was diag-
nosed. In conclusion, a reliable assessment of A phase and
presence/absence of CAA was achieved by a total of 26
observers who examined a standardized set of blocks taken
from only six anatomical regions, applying commercially
available reagents and by assessing them as instructed.
Thus, one may consider rating of A-phases as a diagnostic
tool while analyzing subjects with suspected Alzheimer’s
disease (AD). Because most of these blocks are currently
routinely sampled by the majority of laboratories, assess-
ment of the A phase in AD is feasible even in large scale
retrospective studies.
Introduction
In 1984, Glenner and Wong puriWed and characterized a
novel amyloid protein and in the same year they reported
that patients with both Alzheimer’s disease (AD) and
Down’s syndrome display this unique cerebrovascular
amyloid Wbril protein that has been called -amyloid (A)
protein [11, 12]. Later it became evident that the native
precursor of this A protein was a membrane associated
protein [27]. Subsequently, numerous studies have exam-
ined postmortem brains and evaluated the A seen in the
parenchyma or vessel walls. Most often postmortem brain
material obtained from aged or demented subjects suVering
from clinically presumed AD has been investigated by
applying immunohistochemical (IHC) methodology.
It has generally been considered suYcient to verify the
existence of A-immunoreactive (IR) aggregates in the
parenchyma in only one or at the most few brain regions.
When evaluating the severity of A deposition in relation
to clinical symptoms or the inXuence of various risk factors
on the propensity towards A-IR aggregation investigators
have assessed the type of A aggregates, i.e. diVuse versus
dense, the number of aggregates or the extent of deposits by
means of morphometry [3, 4, 17, 19]. One common Wnding
in aged subjects is the presence of A deposition in vessel
walls, i.e. cerebral amyloid angiopathy (CAA) [25] and this
is also generally assessed during a neuropathological exam-
ination, particularly in subjects with haemorrhages [31]. In
2002, CAA was divided into two types: type 1—CAA is
observed in capillaries with or without CAA in arteries and
veins and type 2—CAA is detected in arteries and veins
[28]. Interestingly, it has been claimed recently that in
particular capillary CAA (type 1), is of signiWcance for
cognitive impairment probably by causing alterations in the
cerebral blood Xow as seen in mouse models for CAA and
AD [7, 14, 30].
The assessment of A in the parenchyma and in the ves-
sel walls has thus become a part of the routine procedure
while handling brains obtained from aged and particularly
demented subjects. In 2008, a large inter-laboratory study
reported that the agreement was poor while assessing the
type (diVuse vs. dense) or the number of IHC detectable A
aggregates and the type of CAA, but instead good results
could be achieved by applying a dichotomized strategy, i.e.
assessment of the presence or absence of A-IR deposits or
CAA [6]. The most disturbing factor was that the above
results were not signiWcantly altered even when the same
antibody provided good IHC staining [6]. The conclusion
was that a more reliable and reproducible method is needed
for the assessment of the severity of A deposition and the
type of CAA in inter-laboratory setting.
In 2002, Thal and colleagues reported that while analyz-
ing 51 postmortem brains, a distinct pattern of involvement
of brain regions with A aggregates could be observed
[29]. The regional involvement was divided into Wve
phases, i.e. deposition of A detected exclusively in neo-
cortex was called phase 1, if additionally in allocortex it
was phase 2, if also in diencephalon and striatum it was
phase 3, if also in brainstem it was phase 4 and Wnally if
also in cerebellum it was termed as phase 5. This stepwise
involvement was considered to be typical for AD [29].
It was considered that in comparison to the assessment
of the type or the density of A-IR lesions, this kind of
dichotomized analysis of A-IR in various regions might
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yield reproducible results even in an inter-laboratory set-
ting [6]. Furthermore, assessment of the regional distribu-
tion might be even more signiWcant than previously
appreciated. Recent studies have indicated that in subjects
with the presenilin-1 mutation the A deposition begins in
striatum, i.e. it does not follow the above progression
[16,  18]. In other studies, A aggregates have been
observed Wrst in deep grey matter structures in dementia
with Lewy bodies [2,  13,  24], Parkinson disease with
dementia [15] and in subjects with stroke [1]. Thus, the
assessment of the distribution of A aggregates in a sub-
ject with AD related tauopathy might be more than rele-
vant since any alteration from the expected pattern may
reXect a genetic alteration or the existence of a signiWcant
concomitant disease process.
The objective of this study was to quantify inter-rater
agreement of 26 neuropathologists who were asked to rate
A deposits in 34 cases by applying the strategy described
by Thal and colleagues [29]. The agreement among
observers while assessing CAA and in particular the type
of CAA was also examined. A second objective was to
identify any pitfalls that might have an impact on the
agreement rates.
Materials and methods
The general working schedule is summarized in Fig. 1.
Sampling of material
Thirty-four cases were included and sampling of blocks
was carried out by one neuropathologist (IA). Ten anatomi-
cal regions were included in this study: 1—cerebellar hemi-
sphere, 2—midbrain with substantia nigra and central grey,
3—striatum (caudate nucleus and putamen) and insular cor-
tex, 4—basal forebrain (with nucleus basalis of Meynert),
amygdala and hypothalamus, 5—cingulated gyrus, 6—hip-
pocampus at the level of lateral geniculate nucleus with CA
regions, remnants of ento rhinal cortex and temporo-occipi-
tal cortex, 7—occipital cortex, visual cortex including cal-
carine  Wssure, 8—temporal cortex, superior and middle
temporal gyrus, 9—parietal cortex, Brodmann area 39/40
and 10-frontal cortex, Brodmann area 9. In all of the exam-
ined cases A-IR deposits were detected.
A total of Wve sets of 7 m-thick sections were produced
from all ten brain areas of the 34 cases. The description of
these cases is provided in Table 1.
Fig. 1 General structure of the study
The participating neuropathologists
Production of sections
5 sets of sections were stained by applying
immunohistochemical methodology 
Primary assessment of the five circulating sets
Each participant assessed the section following the  
instructions given. Results were sent to the  coordinator.
The reference group
5
2
Detailed instructions 
”How to give a phase of Aβ deposition” (Table 3 )
Agreement between participating neuropathologists/ 
observers and the reference group when assessing β-amyloid
immunolabelled lesions while following the recommended 
published strategy (Table 5)
The minimum of regions required for assignment of the β-
amyloid phase (Table 6)
Absence/presence of cerebral amyloid angiopathy (CAA) and 
type 1 CAA in relation to the selection of assessed regions 
(Table 7). 
Staging of selected cases
All sections stained by applying antibodies against β-amyloid
were re-assessed jointly under multi-headed microscope.
Each case was assigned a Aβ phase and the presences of
cerebral amyloid angiopathy (CAA) and capillary CAA were
noted.
3
Design of instructions
Detailed instructions in text, table and figure format were
designed and an assessment sheet was constructed 
(Tables 2, 3, 4  Figures 2,3,4)
4
Joint assessment
During a consensus meeting held around a multi-headed    
microscope, all 34 cases were examined and discussed.  
Pitfalls were identified.      
6
The co-ordinating centre
Summary of results
All detailed results were filed and analyzed. Results which
would be obtained when the number of blocks was reduced
were calculated. 
7
Sampling of the material
Inclusion of blocks (Table 2) was based on the 
recommendations given in the original article (Thal et al
2002). Material included 34 cases with β-amyloid deposits
(Table 1)
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Immunohistochemistry
Five sets of the ten sampled sections were manually stained
by applying IHC methodology. In brief, after rehydration,
one set was pre-treated with 80% formic acid for 6 h and
four sets for 1 h. All Wve sets were subsequently incubated
overnight at 4°C with a monoclonal primary antibody
directed against A. The Wrst set with an antibody from
Dako, clone 6F/3D, dilution 1:100 (Box 1) and four sets
with an antibody from Signet, clone 4G8, dilution 1:2000
(Box 2-5). The reaction product was visualized using the
Power vision detection system (ImmunoVision Technolo-
gies Co., MA, USA) with the use of Biosource Romulin
AEC as the chromogen (Biocare medical, Walnut Creek,
CA, USA).
The members of the reference group (IA, DRT, TA, ND,
HK) jointly re-assessed all cases around a multi-headed
microscope. The reference group assigned each case a
Table 1 Description of the cases included
The phase of -amyloid deposition and the type of cerebral amyloid angiopathy (CAA) when present as assessed by the reference group
a 1—cardiovascular, 2—infections, 3—neoplasia
b 0—CAA not present, 1—CAA in capillaries with or without CAA in arteries and or veins, 2—CAA in arteries and veins
Case Gender Age at death 
years
Clinical signs 
of dementia
Primary cause 
of deatha
Brain weight 
grams
HP- Braak 
stage (10)
-amyloid 
phase (29)
Type of CAAb when 
present (28)
1 Male 65 No 3 1,290 1 1 0
2 Male 82 No 2 1,595 1 1 0
3 Male 85 No 2 1,605 0 1 0
4 Male 64 No 3 1,510 0 2 0
5 Female 72 Yes 1 1,220 3 3 1
6 Female 88 No 1 1,195 1 3 2
7 Female 92 No 1 1,230 2 3 0
8 Male 70 No 1 1,540 2 3 2
9 Female 80 No 1 1,230 1 3 1
10 Female 90 Yes 2 1,260 3 3 2
11 Male 68 No 1 1,340 2 3 1
12 Male 84 No 2 1,370 1 3 1
13 Female 77 Yes 1 1,240 4 4 2
14 Female 95 Yes 2 1,175 4 4 2
15 Male 79 No 1 1,280 2 4 2
16 Female 76 Yes 2 1,200 3 4 0
17 Male 91 Yes 1 1,115 3 4 1
18 Female 82 Yes 2 1,215 5 4 2
19 Male 81 No 1 1,365 4 4 1
20 Female 84 Yes 1 1,365 4 4 1
21 Female 76 Yes 1 1,275 6 5 1
22 Male 76 Yes 1 1,440 6 5 2
23 Female 64 Yes 1 1,150 3 5 1
24 Female 68 Yes 2 1,400 6 5 1
25 Female 86 Yes 1 1,170 4 5 1
26 Male 73 Yes 2 1,390 3 5 2
27 Male 93 Yes 2 1,380 4 5 1
28 Female 82 Yes 2 1,315 5 5 1
29 Female 82 Yes 1 1,360 5 5 1
30 Female 80 Yes 2 1,250 4 5 1
31 Female 81 Yes 1 1,290 3 5 2
32 Male 72 Yes 1 1,245 3 5 2
33 Female 83 Yes 3 1,285 5 5 2
34 Female 61 No 1 1,425 1 5 1Acta Neuropathol (2009) 117:309–320 313
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phase of A deposition and stated whether or not CAA and
capillary CAA could be seen (Table 1) [28, 29]. Further-
more, the results obtained with the two diVerent antibodies
were compared.
Detailed assessment instructions were written by the
reference group. The instructions included a description
of the samples, pictures of the pathology that was present
and expected to be assessed (Figs. 2,  3,  4), general
instructions regarding assessment (Table 2) and tabulated
guidelines (Table 3) on how to designate an A phase.
Furthermore, each participant was urged to read the origi-
nal publications on which the assessment procedure was
based [28, 29].
BNE participant eVorts
Twenty-six participants assessed each case as instructed,
thus each box of Wve produced sets was assessed by Wve to
six examiners. The results were recorded on sheets
(Table 4) which were sent to the coordinating centre. At the
coordination centre, all data found in the assessment sheets
was collected into one Wle (MP). These sheets included
information on whether or not the participant had identiWed
the required neuroanatomical regions, whether or not A-
IR, A-IR plaques, CAA and capillary CAA had been
observed and the designated A phase and CAA type of the
case. In addition, each participant stated whether or not
the distribution of the pathology seemed to progress as
expected, i.e. whether it was a typical or an atypical case.
Consensus meeting and joint assessment
A joint assessment of all IHC labelled sections was carried
out around a multi-headed microscope. The diagnostic fea-
tures of each stage were discussed. While studying the
stained sections under the multi-headed microscope, the
actual observations were compared with the Wled results
that had been collected from the original sheets. Inconsis-
tencies in these observations were discussed and pitfalls
were identiWed.
Analysis of the obtained data
At the coordinating centre, the data found in the assessment
sheet was re-evaluated. With respect to CAA the results
were calculated if only one or some of the sections had
been included. Likewise, the inXuence of a reduction in the
number of brain regions provided on the designation of the
A phase was analyzed. These calculations were carried
out in order to determine the minimum number of neuro-
anatomical regions required to be assessed in order to
achieve the desired result.
Fig. 2 Note the brown cytoplasmic amyloid- labeling seen when applying the 4G8 antibody in neurons and glial cells (a, b, c, d), ependyma (e),
choroid plexus (f) and vessel walls (g). This labeling was not utilized in the classiWcation. MagniWcation £400, scale bar 10 m314 Acta Neuropathol (2009) 117:309–320
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Photomicrograph
Digital images were taken using a Leica DM4000 B micro-
scope equipped with a Leica DFC 320 digital camera.
Results
The results when 26 neuropathologists/observers assessed
the IHC stained sections of the 34 cases by adhering to the
given instructions are summarized in Tables 5 and 6.
The assigned phase while assessing the sections apply-
ing clone 6F3D did not diVer from the results obtained with
clone 4G8. There was only one case in phase 2 (case 4) and
this case was unfortunately not optimal. According to the
reference group, case four (Table 1) fulWlled phase 2 crite-
ria in one stained set while applying clone 4G8 (absolute
agreement 67%) whereas in the remaining 4 sets, the
pathology was seen regionally to such an extent that only
phase 1 criteria were fulWlled (absolute agreement 76%).
Thus the only phase 2 case has been omitted from Table 5.
A-IR pathology was seen by most raters in all cases. In
one case which had been designated as phase 1 by the refer-
ence group, two assessors failed to detect any A-IR
pathology. The overall agreement while assigning the phase
of A deposition in 34 cases was 81% (when case 4 was
excluded the value rose to 84%) while assessing all of the
ten neuroanatomical regions (Table 5). Most of the cases
were considered as being typical, i.e. at least one of the
regions required for designation of that phase was aVected.
Most of the evaluators participated in the consensus
meeting where a joint assessment of the stained sections
under a multi-headed microscope and the previous results
obtained from the assessors were scrutinized. The group as
a whole concluded that all cases were indeed in the phase
designated by the reference group.
When assessing the individual results, it was noted that
only some of the neuroanatomical regions were required in
Fig. 3 Various amyloid- aggregates i.e. plaques, seen here in brown
colour. Fleecy and diVuse (a–e), subpial band-like (f–h), perivascular
lake-like (i) perivascular amyloid- aggregates that are associated with
amyloid angiopathy (j) and diVuse or dense plaques of various sizes
and shapes (k–o). MagniWcation £400, scale bar 10 mActa Neuropathol (2009) 117:309–320 315
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Fig. 4 Cerebral amyloid angiopathy (CAA). Mild (a, b) and moderate
(c) involvement of leptomeningeal arteries and veins. Primarily arterial
and venous (d–h) and primarily capillary (i, j) CAA in the parenchyma
(examples of capillary CAA marked with arrows). Note that parenchy-
mal aggregates i.e. plaques are also seen (d–h). MagniWcation £400,
scale bar 10 m
Table 2 Instructions for the assessment of -amyloid (A) immunoreactive (IR) deposits
Section 1. Cerebellum, hemisphere
Section 2. Midbrain at the level of substantia nigra
Section 3. Striatum including insular cortex
Section 4. Hippocampus (posterior) at the level of the lateral geniculate nucleus
Section 5. Basal forebrain including amygdaloid nuclei and nucleus basalis of Meynert
Section 6. Gyrus cinguli at the level of nucleus basalis of Meynert
Section 7. Occipital cortex (visual cortex including the calcarine Wssure)
Section 8. Parietal cortex, Brodmann areas 39,40
Section 9. Temporal cortex, superior temporal gyrus and part of middle temporal gyrus
Section 10. Frontal cortex, Brodmann area 9
State for each sample whether or not (yes/no) the region to be assessed (Table 4) is identiWed
Note that you should only assess the regions requested and disregard lesions in any other region in a section. In midbrain assess substantia nigra
and periventricular grey and disregard lesions in any other area e.g., in the superior and/or inferior colliculus. In the basal forebrain block assess
amygdaloid nucleus, nucleus basalis of Meynert and hypothalamus, but not globus pallidus etc.
Always ignore cellular A-IR e.g. neuronal or glial cytoplasm and diVuse cytoplasmic labelling of muscle cells (Fig. 2)
State for each assessable and identiWed region whether or not (yes/no) A-IR aggregates are seen. A aggregates refers to both various 
parenchymal A aggregates (Xeecy, diVuse, lake like, dense etc.) (Fig. 3) and A deposits in blood vessels (cerebral amyloid angiopathy), 
i.e. arteries, veins and capillaries (Fig. 4)
State for each identiWable regions whether or not (yes/no) A-IR plaques are seen in the neuropil/parenchyma (Fig. 3)
State for the selected region whether or not (yes/no) CAA is seen (Fig. 4)
State for the selected region whether or not (yes/no) capillary CAA is seen (Fig. 4)
Give a A phase following the instructions given in Table 3. Note, while giving the phase assesses only plaques and ignore CAA
Give a type of CAA, i.e. type 2—CAA is seen in arteries and veins, type 1—CAA is seen in capillaries with or without CAA in veins and arteries316 Acta Neuropathol (2009) 117:309–320
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order to reach a reliable result (Table 6). In all three cases
in phase 1, frontal, occipital or temporo-occipital cortices
were assessed by most observers as being aVected (absolute
agreement 84%), in eight cases in phase 3, remnants of ento
rhinal cortex (phase 2) and amygdaloid nucleus and nucleus
basalis of Meynert (phase 3) were repeatedly aVected
(absolute agreement 80%).
The agreement while assessing CAA in all ten included
sections was as high as 96% (Table 6). Likewise, the agree-
ment was high while assessing leptomeningeal versus paren-
chymal involvement whereas slightly less harmony was
obtained while classifying the type of CAA. There were 16
cases that displayed capillary CAA according to the refer-
ence group and this assessment result was veriWed at the joint
assessment session around the multi-headed microscope. In
six of the cases (cases 9, 11, 21, 27, 28 and 29), most of the
26 assessors had assigned the case as being of type 2, i.e. no
capillary involvement was noted. In all of these cases only
few aVected capillaries were detected in one or two regions
(hippocampus and or occipital cortex). The agreement rates
did not change signiWcantly when the number of blocks to be
assessed was reduced, though the overall results were signiW-
cantly diVerent. The overall detection of CAA dropped from
28 to 22 cases, CAA in parenchyma from 24 to 16 cases and
the number of cases with type 1 CAA, from 10 to 7 cases
(Table 7). The results while assessing CAA in three brain
Table 3 The Wve phases 
of -amyloid deposition 
(Thal et al. 2002)
Phase of Aβ aggregation  Block Region 
1 2 3 4 5 
  +   +   +   r e t t a m   e t i h w / y e r G   x e t r o c   l a t n o r F
  +   +   +   r e t t a m   e t i h w / y e r G   x e t r o c   l a r o p m e T
  +   +   +   r e t t a m   e t i h w / y e r G   x e t r o c   l a t e i r a P
  +   +   +   r e t t a m   e t i h w / y e r G   x e t r o c   l a t i p i c c O
Adjacent temporal cx 
grey/white matter 
One or 
more
regions
with Aβ
One or 
more
regions
with Aβ
+ + + 
Molecular layer of the 
dentate gyrus 
– +/− + + 
  –   4 A C +/− +/− +
  +   +   +   –   1 A C
Hippocampus 
Remnants of entorhinal 
area
– +  +  + 
Gyrus cinguli Grey/white  matter  – 
One or 
more
regions
with Aβ
+ + + 
Hypothalamus –  –  +  + 
Amygdaloid nuclei –  –  +  + 
Basal forebrain 
Nucleus basalis of 
Meynert
– –  + + 
Putamen –  –  +  +  Striatum 
Caudate nucleus –  – 
One or 
more
regions
with Aβ
+ + 
Insular cortex grey/white 
matter 
– +/− ++  +  
Central grey –  –  –  Midbrain
Substantia nigra  – – – 
One or 
more
regions
with Aβ
One or 
more
regions
with Aβ
            m u l l e b e r e C One or 
more
regions
with Aβ
In a typical case detected immu-
noreactivity should be seen as 
given in the table. A case that 
skip’s any of the regions is 
marked as atypical. The anatom-
ical regions that are particularly 
important for a given phase are 
marked in boldActa Neuropathol (2009) 117:309–320 317
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regions, i.e. frontal and occipital cortices and hippocampus
[8] or in the six regions selected above were almost the same
as those obtained while assessing all ten original blocks.
Discussion
While rating the regional distribution of A-IR, i.e. the
phase of A, an 81% agreement was reached when 26
neuropathologists assessed 34 cases all of which displayed
A-IR pathology. The agreement increased to 84%, when
one case, that in most assessment sets displayed phase 1
and in one set phase 2, was excluded. By following the
instructions that were based on the original publication by
Thal and colleagues an agreement from 74 up to 90% could
be achieved by assessing all ten included brain sections
[29]. The lack of a phase 2 case even after a systematic
search from a large original sample was unfortunate
Table 4 Assessment sheet
Section Anatomical
region
Region
identified
yes/no
Aβ + 
aggregates
yes/no 
Aβ plaques 
yes/no
CAA
yes/no
capillary
CAA
yes/no
molecular cell layer       
granular cell layer       
Purkinje cell layer       
White matter       
1.Cerebellum
   Cbl 
leptomeninges        
y e r g l a r t n e c 2.Midbrain
   MB  substantia nigra       
caudate nucleus       
n e m a t u p
3.Striatum  
   STR 
insular cortex       
molecular layer of dentate gyrus       
4 A C
1 A C
remnants of entorhinal cortex       
adjacent temporal cortex       
4.Hippocampus
   ant/post 
   HIPP a/p 
leptomeninges        
hypothalamus      
amygdaloid nuclei       
nucl. basalis of Meynert       
5.Basal forebrain 
   BFB 
leptomeninges        
r e t t a m y e r g
white matter       
6.Gyrus cinguli 
   GC 
leptomeninges        
r e t t a m y e r g
white matter       
7.Occipital cortex 
   Ocx 
leptomeninges        
r e t t a m y e r g
white matter       
8.Parietal cortex 
   Pcx 
leptomeninges        
r e t t a m y e r g
white matter       
9.Temporal cortex 
   Tcx 
leptomeninges        
r e t t a m y e r g
white matter       
10.Frontal cortex 
    Fcx 
leptomeninges        
Note, always ignore cytoplasmic (neurons, glia, muscle cells) staining  
Please highlight the phase (see instructions) and mark whether the case is typical or atypical 
Aβ phase   0 ,    1,     2 ,     3 ,   4,     5  typical / atypical 
Please highlight the type of CAA 
CAA type            1        2  318 Acta Neuropathol (2009) 117:309–320
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however; this might indicate that this phase is quite unusual
or perhaps even virtually non-existent. Only a systematic
assessment of forthcoming cases will resolve this issue.
Interestingly, similar agreement rates and assessment
results were obtained when the number of blocks was
reduced to six. It is noteworthy that these blocks are the
same that are commonly sampled while working with brain
specimens that have to be evaluated either due to the high
age of the deceased or due to an age related neurodegenera-
tive disorder. The hippocampal section and occipital cortex
are assessed when dealing with AD-related tauopathy, basal
forebrain section is evaluated when dealing with tauopa-
thies and especially when one needs to deal with synuclein-
opathy, the midbrain section is examined when dealing
with synucleinopathy, the section obtained from frontal
cortex is assessed when dealing with TAR DNA binding
protein (TDP-43) related pathology and Wnally cerebellum
is evaluated when there is a suspicion of spinocerebellar
ataxias [5, 9, 10, 20–23, 26]. Thus, these six brain sections
are probably sampled in all laboratories during a routine
neuropathological evaluation and consequently the pro-
posed assessment of A phase is quite feasible.
The high agreement here was also related to the fact that
the assessors only had to evaluate the absence or presence
of A-IR pathology and thus the results were not inXuenced
by the previously reported variability in the assessment of
the extent of the pathology [6].
The agreement rates with respect to CAA were also
high. Almost all, 96% of observers noted vascular involve-
ment in the 28 cases in the same way as originally charac-
terized by the reference group and conWrmed in the joint
assessment carried out around a multi-headed microscope.
This result was not altered when only six blocks were
selected.
The agreement was close to 80% in the classiWcation of
the type of CAA, i.e. 76% of assessors had seen capillary
involvement in ten of the included cases. It is noteworthy
that in six cases, most of the observers had failed to detect
capillary CAA and only arterial and/or venous involvement
was registered. In all of these cases, only a few capillaries
in one or two regions were involved. This result emphasises
that mild capillary involvement even after assessing numer-
ous brain regions might easily be overlooked. The reliable
assessment of capillary CAA is of particular importance in
Table 5 The -amyloid phase reported by 26 observers when following the original instructions and while assessing 10 selected brain blocks
The absolute agreement between 26 observers and the reference group is given in bold
Number of cases -amyloid phase (Thal et al. 2002) Absolute agreement in percent
Reference phase 0 1 2 3 4 5 All phases
31 2 86 42 684
2
83 1 1 81 11 6
84 1 5 74 11
14 5 2 8 90
Table 6 Agreements while assessing cerebral amyloid angiopathy (CAA)
a Frontal and occipital cortices and hippocampus
b Cases 5, 12, 17, 19, 20, 23, 24, 25, 30 and 34
c Cases 5, 12, 17, 19, 23, 24, 25, 30 and 34
d Cases 5, 12, 17, 19, 23, 24, 30
e Cases 5, 12, 17,19, 23, 24, 25, 30 and 34
Absolute agreement (ABS) among 26 assessments while assessing various selections of blocks 
All ten blocks (Table 4)  Three selected blocks
a Occipital cortex only  Blocks as listed in Table 7 
Type of pathology 
Number of 
cases
ABS in 
percent 
Number of 
cases
ABS in 
percent 
Number of 
cases
ABS in 
percent 
Number of 
cases
ABS in 
percent
CAA  detected  28  96  28 92 22 89 28 93 
Leptomeningeal CAA seen  27  94  27  85  20  92  27  93 
Parenchymal  CAA  seen  24  86  21 90 16 84 21 87 
Type 1 CAA seen  10
b 76 9
c 72 7
d 75 9
e 74Acta Neuropathol (2009) 117:309–320 319
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subjects with dementia lacking any other pathological alter-
ations that can be considered as causative with respect to
the clinical syndrome.
Here we noted that when only one cortical region was
assessed, the agreement rates dropped marginally but more
importantly the detection of CAA and particularly capillary
CAA did change signiWcantly, declining from 10 to 7 cases.
Capillary CAA in one brain region has been assessed by
Attems and Jellinger in 2004 [7] and by Jeynes and Provias
in 2006 [14]. Both groups reported a signiWcant correlation
between capillary CAA and AD lesions. Based on our
results, the strong association between AD lesions and capil-
lary CAA should probably be re-evaluated including a larger
number of regions. In 2008, Attems and colleagues reported
a low prevalence of intracerebral haemorrhage in sporadic
CAA when they assessed CAA in frontal and occipital corti-
ces and also hippocampus [8]. While applying their strategy,
including these three brain areas in the assessment, all 28
subjects with CAA were identiWed and in nine out of ten
cases type 1 CAA was detected by most of the observers.
Thus, by assessing these three blocks essentially equivalent
results can be achieved as by assessing all ten blocks.
In epidemiological studies, one may need to assess huge
sample sizes, e.g. thousands of cases. This is also the case
when searching for risk genes. In both situations, material
obtained from several laboratories will need to be combined.
Furthermore, not only numerous samples need to be evalu-
ated but they also have to be reliably and reproducibly char-
acterized. Here we report that a high agreement can be
achieved while assessing the regional distribution of A-IR
pathology and the absence/presence of CAA. With respect of
capillary CAA, it should be borne in mind that a mild focal
capillary CAA might be overlooked whereas in those cases
where there is moderate involvement, the agreement regard-
ing the detection of type 1 CAA is rather high. This reliable
assessment of A phase, presence/absence of CAA and
type 1 CAA was reached by staining a standardized set of
blocks taken from six neuroanatomical regions and by apply-
ing a commercially available reagent. The investigators were
requested to follow written instructions. It is noteworthy that
most of the blocks included here are currently routinely sam-
pled by the majority of laboratories and thus even large scale
retrospective studies could be organized. Therefore, determi-
nation of the phase of A-deposition may represent a reliable
and reproducible tool to describe and quantify AD related A
pathology in post-mortem brain specimens.
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Table 7 The six blocks 
required while assessing the 
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Phase of Aβ aggregation Block Region 
1 2 3 4 5 
Frontal cortex  Grey matter 
Occipital cortex  Grey matter 
Adjacent temporal cx 
grey matter 
One or 
more
regions
with Aβ
+/− +/− +/− +/−
Molecular layer of the 
dentate gyrus 
CA4
CA1
Hippocampus 
Remnants of entorhinal 
area
– One or 
more
regions
with Aβ
+/− +/− +/−
Hypothalamus
Amygdaloid nuclei 
Basal forebrain 
Nucleus basalis of 
Meynert
– –  One or 
more
regions
with Aβ
+/− +/−
Central grey  Midbrain
Substantia nigra 
– – –  One or 
more
regions
with Aβ
+/−
Cerebellum Molecular cell layer          With Aβ
In a typical case, the detected 
immunoreactivity is seen as 
described in the table. A case 
that by passes any of the regions 
is assigned as being atypical320 Acta Neuropathol (2009) 117:309–320
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